Zytiga results 'transformational' says Janssen's oncology VP

2 June 2017

As the annual meeting of the American Society of Clinical Oncology gets underway in Chicago, investors, competitors and industry watchers eagerly await results of Janssen’s LATITUDE trial of Zytiga (abiraterone) in prostate cancer.

The presentation will form part of the plenary session at ASCO, one of only a handful of submissions to be selected for this, the most prominent placement.

Craig Tendler, VP of late stage development in oncology, says: "I think that this fact speaks for the impactfulness of the results. It's a very good indication that the results are transformational."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK